Aspirin to prevent heart attack and stroke : What's the right dose?DALEN, James E.The American journal of medicine. 2006, Vol 119, Num 3, pp 198-202, issn 0002-9343, 5 p.Article

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia?DALEN, James E.The American journal of medicine. 2008, Vol 121, Num 6, pp 458-463, issn 0002-9343, 6 p.Article

Economy class syndrome: Too much flying or too much sitting?DALEN, James E.Archives of internal medicine (1960). 2003, Vol 163, Num 22, pp 2674-2676, issn 0003-9926, 3 p.Article

Pulmonary embolism: What have we learned since virchow? Natural history, pathophysiology, and diagnosisDALEN, James E.Chest. 2002, Vol 122, Num 4, pp 1440-1456, issn 0012-3692Article

ACCP conference on antithrombotic therapy, June 21, 1988DALEN, James E; HIRSH, Jack.Chest. 1989, Vol 95, Num 2, issn 0012-3692, A-D, 1S-168S [173 p.]Conference Proceedings

Is the Campaign to Prevent VTE in Hospitalized Patients Working?STEIN, Paul D; MATTA, Fadi; DALEN, James E et al.Chest (American College of Chest Physicians). 2011, Vol 139, Num 6, pp 1317-1321, issn 0012-3692, 5 p.Article

ACCP Concensus Conference on Antithrombotic TherapyDALEN, James E; HIRSH, Jack.Chest. 1998, Vol 114, Num 5, issn 0012-3692, 335 p., SUPConference Proceedings

Medicolegal implications of the consensus conference, with special attention to the fifth antithrombotic therapy consensus conferenceMCINTYRE, K. M.Chest. 1998, Vol 114, Num 5, pp 742S-747S, issn 0012-3692, SUPConference Paper

Medicolegal implications of consensus statementsMCINTYRE, K. M.Chest. 1995, Vol 108, Num 4, pp 502S-505S, issn 0012-3692, SUPConference Paper

Clinicians' responses to direct-to-consumer advertising of prescription medicationsZACHRY, Woodie M; DALEN, James E; JACKSON, Terrence R et al.Archives of internal medicine (1960). 2003, Vol 163, Num 15, pp 1808-1812, issn 0003-9926, 5 p.Article

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass graftsSTEIN, Paul D; DALEN, James E; GOLDMAN, Steven et al.Chest. 2001, Vol 119, Num 1, pp 278S-282S, issn 0012-3692, SUPArticle

Antithrombotic therapy in peripheral arterial occlusive diseaseJACKSON, M. R; CLAGETT, G. P.Chest. 1998, Vol 114, Num 5, pp 666S-682S, issn 0012-3692, SUPConference Paper

Antithrombotic therapy in childrenMICHELSON, A. D; BOVILL, E; ANDREW, M et al.Chest. 1995, Vol 108, Num 4, pp 506S-522S, issn 0012-3692, SUPConference Paper

Minor Injuries as a Risk Factor for Venous Thrombosis. CommentaryDALEN, James E; VAN STRALEN, Karlijn J; ROSENDAAL, Frits R et al.Archives of internal medicine (1960). 2008, Vol 168, Num 1, issn 0003-9926, 14-15, 21-26 [8 p.]Article

New antithrombotic agentsWEITZ, J. I; HIRSH, J.Chest. 1998, Vol 114, Num 5, pp 715S-727S, issn 0012-3692, SUPConference Paper

Antithrombotic therapy in peripheral arterial occlusive diseaseCLAGETT, G. P; KRUPSKI, W. C.Chest. 1995, Vol 108, Num 4, pp 431S-443S, issn 0012-3692, SUPConference Paper

Use of antithrombotic agents during pregnancyGINSBERG, J. S; HIRSH, J.Chest. 1998, Vol 114, Num 5, pp 524S-530S, issn 0012-3692, SUPConference Paper

Platelet-active drugs : The relationships among dose, effectiveness, and side effectsPATRONO, Carlo; COLLER, Barry; DALEN, James E et al.Chest. 2001, Vol 119, Num 1, pp 39S-63S, issn 0012-3692, SUPArticle

Antithrombotic therapy in atrial fibrillationLAUPACIS, A; ALBERS, G; DALEN, J et al.Chest. 1998, Vol 114, Num 5, pp 579S-589S, issn 0012-3692, SUPConference Paper

Making decisions about antithrombotic therapy in heart disease : Decision analytic and cost-effectiveness issuesECKMAN, M. H; LEVINE, H. J; SALEM, D. N et al.Chest. 1998, Vol 114, Num 5, pp 699-714, issn 0012-3692, SUPConference Paper

Hemorrhagic complications of anticoagulant treatmentLEVINE, M. N; RASKOB, G; LANDEFELD, S et al.Chest. 1998, Vol 114, Num 5, pp 511S-523S, issn 0012-3692, SUPConference Paper

Prevention of venous thromboembolismCLAGETT, G. P; ANDERSON, F. A; GEERTS, W et al.Chest. 1998, Vol 114, Num 5, pp 531S-560S, issn 0012-3692, SUPConference Paper

Heparin and low-molecular-weight heparin : Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safetyHIRSH, Jack; WARKENTIN, Theodore E; SHAUGHNESSY, Stephen G et al.Chest. 2001, Vol 119, Num 1, pp 64S-94S, issn 0012-3692, SUPArticle

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valvesSTEIN, P. D; ALPERT, J. S; DALEN, J. E et al.Chest. 1998, Vol 114, Num 5, pp 602S-610S, issn 0012-3692, SUPConference Paper

Coronary thrombolysisCAIRNS, J. A; KENNEDY, J. W; FUSTER, V et al.Chest. 1998, Vol 114, Num 5, pp 634S-657S, issn 0012-3692, SUPConference Paper